Carfilzomib

KYPROLIS®

Overview

Carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is approved for use with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma in patients who have received one to three prior lines of therapy. Carfilzomib is injected into a vein through an IV.

SparkCures ID 2
Developed By Amgen
Brand Name Kyprolis®
Generic Name Carfilzomib
Additional Names PR-171
Treatment Classifications
Tags
  • FDA Approved

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources